Clinical characteristics and cerebrospinal fluid parameters in patients with peripheral facial palsy caused by Lyme neuroborreliosis compared with facial palsy of unknown origin (Bell's palsy) by Bremell, Daniel & Hagberg, Lars
RESEARCH ARTICLE Open Access
Clinical characteristics and cerebrospinal fluid
parameters in patients with peripheral facial palsy
caused by Lyme neuroborreliosis compared with
facial palsy of unknown origin (Bell’s palsy)
Daniel Bremell
* and Lars Hagberg
Abstract
Background: Bell’s palsy and Lyme neuroborreliosis are the two most common diagnoses in patients with
peripheral facial palsy in areas endemic for Borrelia burgdorferi. Bell’s palsy is treated with corticosteroids, while
Lyme neuroborreliosis is treated with antibiotics. The diagnosis of Lyme neuroborreliosis relies on the detection of
Borrelia antibodies in blood and/or cerebrospinal fluid, which is time consuming. In this study, we retrospectively
analysed clinical and cerebrospinal fluid parameters in well-characterised patient material with peripheral facial
palsy caused by Lyme neuroborreliosis or Bell’s palsy, in order to obtain a working diagnosis and basis for
treatment decisions in the acute stage.
Methods: Hospital records from the Department of Infectious Diseases, Sahlgrenska University Hospital, for patients
with peripheral facial palsy that had undergone lumbar puncture, were reviewed. Patients were classified as Bell’s
palsy, definite Lyme neuroborreliosis, or possible Lyme neuroborreliosis, on the basis of the presence of Borrelia
antibodies in serum and cerebrospinal fluid and preceding erythema migrans.
Results: One hundred and two patients were analysed; 51 were classified as Bell’s palsy, 34 as definite Lyme
neuroborreliosis and 17 as possible Lyme neuroborreliosis. Patients with definite Lyme neuroborreliosis fell ill
during the second half of the year, with a peak in August, whereas patients with Bell’s palsy fell ill in a more
evenly distributed manner over the year. Patients with definite Lyme neuroborreliosis had significantly more
neurological symptoms outside the paretic area of the face and significantly higher levels of mononuclear cells and
albumin in their cerebrospinal fluid. A reported history of tick bite was uncommon in both groups.
Conclusions: We found that the time of the year, associated neurological symptoms and mononuclear pleocytosis
were strong predictive factors for Lyme neuroborreliosis as a cause of peripheral facial palsy in an area endemic for
Borrelia. For these patients, we suggest that ex juvantibus treatment with oral doxycycline should be preferred to
early corticosteroid treatment.
Background
Peripheral facial palsy occurs in the general population,
with an annual incidence of 20-53 per 100,000 [1,2]. In
areas endemic for Borrelia burgdorferi (Bb), Lyme neuro-
borreliosis (LNB) is estimated to cause 2-25% of peripheral
facial palsy cases [3-6]. The remaining cases are caused
by a wide range of diagnoses, such as Ramsay Hunt
syndrome, sarcoidosis, Sjögren’s syndrome, tumours and
acute idiopathic peripheral facial palsy, also known as
Bell’s palsy (BP). Of these, BP constitutes by far the largest
group, causing 60-75% of cases of peripheral facial palsy
[2,7]. While LNB is treated with oral doxycycline or intra-
venous ceftriaxone, early treatment (within 72 hours) with
corticosteroids improves the outcome in BP [8-12]. In
order to choose the right treatment, it is important to dif-
ferentiate between these two conditions. Antibodies to Bb
in serum and cerebrospinal fluid (CSF) are often helpful in
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obtain the analysis results. Furthermore, no data are avail-
able regarding the optimal treatment of patients with BP
who present more than 72 hours after the onset of symp-
toms [8]. At the time of admission, the treatment decision
must therefore frequently be based on patient history, phy-
sical examination and cerebrospinal fluid analysis of leuko-
cytes, albumin and glucose, which can be obtained within
hours. There is no time to wait for the results of other
analyses. The aim of this study was retrospectively to ana-
lyse clinical and CSF parameters in well-characterised
patient material with LNB and BP, where an acute lumbar
puncture had been performed, in order to obtain a base
for treatment decisions.
Methods
Patients
Hospital records for all the patients that presented at, or
were referred to, the Department of Infectious Diseases,
Sahlgrenska University Hospital, Gothenburg, Sweden,
with peripheral facial palsy and in whom a lumbar punc-
ture had been performed, between February 2000 and
February 2009, were reviewed. Data on specific medical
history, clinical characteristics and laboratory parameters
were collected. Patients with peripheral facial palsy with
causes other than LNB or BP were excluded.
Case definitions
Patients were classified as BP, definite LNB, or possible
LNB. Patients with Bb antibodies below the upper refer-
ence level in both serum and CSF, and with no history of
erythema migrans (EM) within 3 months before the
onset of neurological symptoms and with no other causes
of peripheral facial palsy, were classified as BP. Patients
with Bb antibodies (IgG and/or IgM) above the upper
reference level in CSF and either a positive Bb antibody
index or the presence of ≥ 2 oligoclonal bands on isoelec-
tric focusing of CSF and serum, or with a history of EM
within 3 months before the onset of neurological symp-
toms, were classified as definite LNB. Patients with Bb
antibodies above the upper reference level in CSF and/or
serum but with a negative Bb antibody index and < 2 oli-
goclonal bands on isoelectric focusing of CSF and serum
and with no history of EM within 3 months before the
onset of neurological symptoms were classified as possi-
ble LNB. The Bb antibody index was calculated as the
ratio of the CSF/serum quotient of specific antibodies to
the corresponding CSF/serum quotient of total immuno-
globulins. Antibody index values of > 1.4 were considered
positive [13].
For clarity, comparisons of clinical characteristics and
laboratory parameters were made mainly between the defi-
nite LNB and BP groups, with the possible LNB group
described in more detail separately. CSF pleocytosis was
deliberately not used as a diagnostic criterion, since
one aim of the study was to analyse differences in CSF
parameters between the groups.
A subgroup analysis was made of patients with periph-
eral facial palsy without associated neurological symptoms.
Laboratory tests
Two different tests were used to analyse Bb antibodies in
serum and CSF during the study period. Until 26 June
2006, antibodies were analysed using an enzyme-linked
immunosorbent assay (ELISA) kit for IgG and IgM antibo-
dies (Dako Lyme Borreliosis Kit, Dako). Tests positive for
IgM were further analysed with a more specific test
(IDEIA, Dako). After 26 June 2006, Bb antibodies were
analysed using a sandwich chemiluminescence immunoas-
say (CLIA) test kit (LIASON, DiaSorin).
Statistics
Results were analysed using a statistical software package
(PASW Statistics 18.0). For the analysis of unpaired cate-
gorical data, Pearson’s c
2 test was used. As the quantitative
measures showed a markedly skewed distribution, they
were analysed using the non-parametric Mann-Whitney
U test. Quantitative variables are presented as the median
(range). p-values of < 0.05 were considered statistically
significant.
Ethics
The study was approved by the Regional Ethical Review
Board, Gothenburg, Sweden.
Results
Hospital records for 109 patients were reviewed. Seven
patients diagnosed with diseases other than LNB or BP
were excluded (5 patients with Ramsay Hunt syndrome, 1
with brain stem infarction, 1 with erysipelas). In all, 102
patients were analysed; 51 were classified as BP, 34 as defi-
nite LNB and 17 as possible LNB. Of the patients diag-
nosed as definite LNB, 30 had a positive Bb antibody
index. Of the remaining 4 patients, 2 had ≥ 2 oligoclonal
bands (IgG or IgM) on isoelectric focusing of CSF and
serum, while 2 had a preceding EM.
Patients with definite LNB were older than patients
with BP, median age 46 (range 7-75) and 36 (range 15-
70) respectively, and fell ill during the second half of the
year, with a peak in August, whereas patients with Bell’s
palsy fell ill in a more evenly distributed manner over the
year (Figure 1). Patients with definite LNB more com-
monly had neurological symptoms outside the paretic
area of the face than patients with BP; these symptoms
included radiculitic pain (50% and 10% respectively, p <
0.001), sensibility disturbances (24% and 0%, p < 0.001)
and pareses (9% and 0%, p = 0.03). Symptoms from the
affected side of the face were equally common in both
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sensibility disturbances (6% and 12%). A reported history
of tick bite within 3 months before the onset of symp-
toms was uncommon in both groups and there was no
significant difference, 29% of definite LNB patients, 14%
of BP patients (p = 0.08) (Table 1).
All the patients in the definite LNB group had an ele-
v a t e dn u m b e ro fC S Fm o n o n u c l e a rc e l l s( r e f .<5 / μL),
compared with 20% in the BP group. The median CSF
mononuclear cell count in the definite LNB group was
165/μL (32-1044), while it was 2/μL (0-534) in the BP
group (p < 0.001). CSF albumin levels were also signifi-
cantly higher in the definite LNB group, median 840 mg/
L (197-2850), than in the Bell’sp a l s yg r o u p ,m e d i a n
196 mg/L (76-768) (p < 0.001) (Table 1).
The patients in the possible LNB group did not differ
significantly from the patients in the BP group in any of
the clinical characteristics or laboratory parameters
described above. However, they differed significantly from
the definite LNB patients in neurological symptoms out-
side the affected area of the face, radiculitic pain (6% and
50% respectively, p = 0.006) and sensibility disturbances
Figure 1 Month of onset of symptoms. Number of patients per month presenting with peripheral facial palsy for the groups Bell’s palsy and
definite Lyme neuroborreliosis.
Table 1 Baseline data, clinical characteristics and CSF laboratory data
Bell’s palsy
(n = 51)
Definite Lyme
neuroborreliosis
(n = 34)
Possible Lyme
neuroborreliosis
(n = 17)
p*
Gender, female 26 (51%) 13 (38%) 7 (41%)
Age 36 (15-70) 46 (7-75) 28 (8-70) 0.04
Tick bite within 3 months 7 (14%) 10 (29%) 4 (24%) 0.08
Symptoms
Local pain, affected side of face 17 (33%) 17 (50%) 7 (41%) 0.43
Radiculitic pain, other location 5 (10%) 17 (50%) 1 (6%) < 0.001
Local sensibility disturbances 6 (12%) 2 (6%) 2 (12%) 0.36
Other sensibility disturbances 0 (0%) 8 (24%) 1 (6%) < 0.001
Other pareses 0 (0%) 3 (9%) 1 (6%) 0.03
No associated neurogical symptoms 25 (49%) 6 (18%) 7 (41%)
Duration of symptoms before LP, days 5 (1-90) 14 (1-75) 12 (2-120)
CSF laboratory data
Mononuclear cells, no/μL 2 (0-534) 165 (32-1044) 3 (0-41) < 0.001
Albumin, mg/L 196 (76-768) 840 (197-2850) 204 (66-774) < 0.001
Comparison between patients with peripheral facial palsy diagnosed as Bell’s palsy, definite Lyme neuroborreliosis or possible Lyme neuroborreliosis. Data for
gender, history of tick bite and symptoms are presented as number of patients (percentage of total for the group). Data for numerical values are presented as
median (range). *p-values refer to the comparison between the groups with Bell’s palsy and definite Lyme neuroborreliosis.
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meters, mononuclear cells (median 3/μL [0-41] and med-
ian 165/μL [32-1044] respectively, p < 0.001), and albumin
(median 204 mg/L [66-774] and 840 mg/L [197-2850],
p < 0.001) (Table 1).
Thirty-eight patients had no associated neurological
symptoms and were analysed as a subgroup; 25 patients
with BP, 6 with definite LNB, 7 with possible LNB.
Among these patients, the median CSF mononuclear cell
count in the definite LNB group was 103/μL (40-1044),
while it was 2/μL (0-36) in the BP group (p < 0.001). CSF
albumin levels were also significantly higher in the defi-
nite LNB group, median 988 mg/L (444-1520), than in
the Bell’s palsy group, median 194 mg/L (107-569) (p <
0.001) (Table 2).
Discussion
Peripheral facial palsy of unknown origin (Bell’sp a l s y )i s
a disease with a large number of differential diagnoses
[14]. In our study, we required evidence of intrathecally
produced antibodies or preceding erythema migrans for a
definite LNB diagnosis. Intrathecal antibody production
is generally used for a definite diagnosis, but it has low
sensitivity in the very early phase of the disease [15]. In
general, patients with LNB display intrathecally produced
antibodies within two weeks of the onset of symptoms,
but in some patients antibody production may be delayed
for up to six weeks, which poses a diagnostic problem
[16,17]. Furthermore, both the culture of CSF for Bb and
the detection of Bb i nC S Fb ys p e c i f i cP C Ra n a l y s i sh a v e
av e r yl o ws e n s i t i v i t ya n da r en o tu s e di nc l i n i c a lr o u t i n e
[18]. It is therefore difficult completely to rule out the
possibility that some patients with LNB were classified as
BP, especially since patients diagnosed as BP underwent
LP earlier than patients diagnosed as LNB (definite or
possible) (Table 1). However, clinical follow-up did not
change the diagnosis in any patient with BP. With these
diagnostic drawbacks, there will always be some patients
for whom the diagnosis is difficult and who will be
classified as unknown. On the other hand, using only
serum antibodies against Bb as a diagnostic criterion will
produce a large number of false positive cases, since the
seroprevalence of antibodies against Bb is high in the
general population; 7-29% in endemic areas of Sweden
[19,20].
The possible LNB group in the study (who had Bb anti-
bodies in serum but not in CSF and no history of EM)
did not differ significantly from the BP patients in terms
of clinical characteristics or laboratory parameters and
did not, as a median, display mononuclear pleocytosis or
elevated albumin in CSF. We interpreted this as a reflec-
tion of the high seroprevalence of Bb antibodies in the
population, rather than a Bb infection as the aetiology of
peripheral facial palsy.
Among the 38 patients without associated neurological
symptoms that were analysed as a subgroup, BP patients,
as expected, constituted the majority, 66% (n = 25), and
patients with possible LNB 18% (n = 7). However, 16%
(n = 6) of these patients were diagnosed as definite LNB,
showing that the absence of associated neurological
symptoms does not exclude LNB as a cause of peripheral
facial palsy. The differences in the CSF mononuclear cell
count and albumin levels were also significant in the sub-
group analysis, underlining the importance of CSF sam-
pling in the diagnosis of LNB.
The observed seasonal variation in the incidence of
peripheral facial palsy caused by LNB, with a peak in
late summer/early autumn and no cases during late win-
ter/early spring, confirms previous studies and co-varies
with the tick-feeding season. The absence of any cases
outside that season is also evidence that the incubation
period for LNB is rarely more than a couple of weeks,
as previously described [3,5,6,21].
The differing clinical picture between peripheral facial
palsy caused by LNB and BP, with a higher occurrence of
neurological symptoms outside the cranial nerve area in
peripheral facial palsy caused by LNB, is broadly in accor-
dance with previous studies. Two small, early studies
Table 2 Subgroup analysis of patients without associated neurological symptoms
Bell’s Palsy
(n = 25)
Definite Lyme
Neuroborreliosis
(n = 6)
Possible Lyme
Neuroborreliosis
(n = 7)
p*
Gender, female 16 (64%) 1 (17%) 4 (57%)
Age 36 (15-70) 33 (19-67) 27 (8-70) 0.84
Tick bite within 3 months 2 (8%) 3 (50%) 3 (43%) 0.12
Duration of symptoms before LP, days 3 (1-25) 3 (1-42) 12 (2-120)
CSF laboratory data
Mononuclear cells, no/μL 2 (0-36) 103 (40-1044) 3 (1-14) < 0.001
Albumin, mg/L 194 (107-569) 988 (444-1520) 175 (66-279) < 0.001
Comparison between patients with peripheral facial palsy diagnosed as Bell’s palsy, definite Lyme neuroborreliosis or possible Lyme neuroborreliosis and no
associated neurological symptoms. Data for gender and history of tick bite are presented as number of patients (percentage of total for the group). Data for
numerical values are presented as median (range). *p-values refer to the comparison between the groups with Bell’s palsy and definite Lyme neuroborreliosis
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toms that predict LNB, whereas a larger study from 2002
describes headache, arthralgia and enlarged cervical
lymph nodes [3,4,6]. What is not usually described, how-
ever, is the high percentage of patients with BP that
describe pain from the affected area of the face (43%).
A reported history of tick bite was uncommon in the
definite LNB group (29%). The same low numbers have
also been seen in some earlier studies, while other stu-
dies have suggested the use of a history of tick bite in
discriminating between BP and LNB [5,22,23]. It is
therefore important to stress that the absence of a tick
bite history does not exclude LNB.
The present study was performed at a department,
which mainly treats adult patients. Consequently, the age
of the patients in this study is not fully representative of
all patients with BP or LNB. However, the median ages of
the respective groups are similar to those reported pre-
viously. Patients with definite LNB were older than
patients with BP, median age 46 (7-75) and 36 (15-70)
respectively. This is in line with the bimodal age distribu-
tion of LNB, with a median in the fifth decade of life and
with the reported peak incidence of BP around the second
to fifth decade of life [14,24].
One aim of this study was to analyse differences in CSF
parameters between the definite LNB and BP patient
groups. It was therefore not possible to use CSF mononuc-
lear pleocytosis as a diagnostic criterion for LNB. In spite
of this, we found that time during the year, presence of
neurological symptoms outside the affected area of the
face and mononuclear pleocytosis in CSF were strong pre-
dictive factors for LNB. All these data are possible to
obtain within hours after admission, which can be of help
in the choice of acute treatment.
Conclusions
We found that the time of the year, associated neurologi-
cal symptoms and mononuclear pleocytosis in CSF were
strong predictive factors for LNB as a cause of peripheral
facial palsy in an area endemic for borreliosis. For these
patients, we suggest that ex juvantibus treatment with
oral doxycycline should be preferred to early corticoster-
oid treatment.
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